Abstract
Plexus Corp. will report fiscal third-quarter 2026 results on July 29, 2026 (Post-Mkt); this preview summarizes last quarter’s performance and the current quarter’s consensus outlook for revenue, profitability, and adjusted EPS, and compiles recent institutional views to frame the near-term setup.
Market Forecast
Consensus for fiscal third-quarter 2026 points to revenue of 1.23 billion US dollars, up 20.36% year over year; adjusted EPS is projected at 2.12, up 23.72% year over year, and EBIT is estimated at 75.30 million US dollars, implying 29.02% year-over-year growth. Forecasts do not include explicit targets for gross margin or net profit margin; however, the implied operating margin from revenue and EBIT estimates is approximately 6.12%.
Plexus Corp.’s main business remains broadly balanced across Industrial and Healthcare/Life Sciences, supported by the ongoing execution of program ramps and operational efficiency initiatives. Within the portfolio, Healthcare/Life Sciences stands out as the most promising near-term contributor, anchored by last quarter revenue of 472.87 million US dollars and benefiting from the company’s projected 20.36% year-over-year revenue expansion this quarter.
Last Quarter Review
Plexus Corp. delivered fiscal second-quarter 2026 revenue of 1.16 billion US dollars, up 18.73% year over year, a gross profit margin of 10.24%, GAAP net income attributable to shareholders of 49.81 million US dollars with a 4.28% net profit margin, and adjusted EPS of 2.05, up 23.49% year over year. Net profit improved 20.95% sequentially, reflecting solid operating leverage and disciplined execution as volumes scaled through the quarter.
Business mix was balanced: Industrial generated 478.67 million US dollars, Healthcare/Life Sciences generated 472.87 million US dollars, and Aerospace/Defense contributed 212.22 million US dollars; group revenue grew 18.73% year over year.
Current Quarter Outlook
Main Business Momentum and Profitability Trajectory
The consensus revenue estimate of 1.23 billion US dollars for fiscal third-quarter 2026 implies a meaningful step-up against the prior-year period and builds on last quarter’s 18.73% year-over-year growth. With EBIT expected at 75.30 million US dollars, the implied operating margin of about 6.12% suggests incremental margin capture versus the scale of revenue expansion, consistent with a scenario where utilization, mix, and productivity continue to trend favorably. While gross margin guidance is not explicitly available, the last reported 10.24% and the accelerated EBIT growth forecast of 29.02% year over year signal leverage that typically accompanies higher throughput and maturing program ramps.
Adjusted EPS is projected at 2.12, up 23.72% year over year, aligning with the stronger operating income outlook. The composition of this EPS trajectory links to volume growth across core end-markets and the financial discipline evident in recent quarters. Although net margin guidance is not provided, the prior quarter’s net profit margin of 4.28% and the sequential net profit growth of 20.95% provide a constructive base for incremental earnings expansion if revenue and operating income meet estimates.
Cash conversion and working-capital cadence often influence reported earnings quality in this business, especially around large program transitions. A continuation of disciplined inventory and receivables management would support free cash flow and reduce earnings volatility. From a cost perspective, sustained focus on supply-chain normalization and factory efficiency should help defend margins as volumes shift among programs and customers through the fiscal year.
Most Promising Segment: Healthcare/Life Sciences
Healthcare/Life Sciences, with 472.87 million US dollars of revenue in the last reported quarter, is positioned to be a leading engine for this quarter’s earnings profile. This segment’s revenue scale is nearly on par with Industrial, yet it tends to benefit from more complex assemblies and longer-life programs that can provide better visibility once ramped. The consensus view of 20.36% revenue growth at the company level this quarter frames a favorable backdrop for the segment’s contribution, particularly if higher-value programs sustain strong demand.
Margin dynamics in Healthcare/Life Sciences can be supportive in periods of stable ramp execution and efficient yields, providing a cushion for consolidated gross margin and EBIT. Given the forecasted 29.02% year-over-year increase in EBIT, contributions from higher-mix healthcare programs may help drive incremental profitability beyond simple volume uplift. If program stability and throughput continue to improve, Healthcare/Life Sciences could outpace company-level EPS growth by sustaining richer margins, though the precise segment-level growth rate is not disclosed.
Operationally, the key watch items this quarter include program lifecycle maturity, yield progression, and the balance of new wins versus end-of-life transitions. Execution that minimizes start-up inefficiencies while expanding capacity where needed should allow this segment to translate top-line demand into stronger operating leverage. In addition, any evidence of steady order intake and backlog support would bolster confidence in the durability of growth into the fiscal fourth quarter.
Key Stock Price Drivers This Quarter
The first swing factor is the revenue print versus the 1.23 billion US dollars estimate and any qualitative color on the run-rate into fiscal fourth-quarter 2026. Given the last quarter’s upside to both revenue and adjusted EPS, investors are attuned to whether the company can deliver another quarter broadly in line with or exceeding expectations without sacrificing margin quality. Commentary on visibility, order conversion, and program ramps will shape the trajectory of estimates into year-end.
The second driver is margin commentary, particularly the relationship between gross margin and EBIT expansion. With EBIT growth forecast to run ahead of revenue growth on a year-over-year basis, the market will look for confirmation that efficiencies and mix are improving rather than being temporarily buoyed by one-off factors. Stable or upward-trending operating leverage would validate the 23.72% year-over-year EPS growth expectation, while any indication of rising input or labor costs pressuring gross margin could temper sentiment even if top-line meets estimates.
A third factor is management transition and operating cadence. The planned CFO transition announced earlier this fiscal year highlights succession and continuity in financial leadership. Investors will assess whether financial priorities—disciplined capital allocation, consistent working-capital turns, and steady free cash flow—are progressing as planned. Clear communication around cash generation and investment needs to support program ramps can alleviate concerns about scaling costs as the revenue base grows.
Finally, qualitative signals around backlog, bookings, and the cadence of program wins may influence how investors frame fiscal 2026 exit rates. A constructive tone on orders consistent with the 20.36% year-over-year revenue estimate could sustain a positive revision cycle. Conversely, any indication of push-outs or timing-related shifts among large customers would introduce uncertainty around the revenue slope into the fiscal fourth quarter, affecting near-term valuation multiples.
Analyst Opinions
Bullish views constitute 100% of the recent opinions compiled in this window, with institutional commentary highlighting operational momentum and upside to earnings power. A notable example is the reiterated Buy rating and 206 US dollars price target from Needham, which cited a strong start to fiscal 2026 and an upgraded outlook, underscoring confidence in execution and earnings trajectory. Supportive elements in the bullish case include consensus expectations for 20.36% year-over-year revenue growth, 29.02% year-over-year growth in EBIT, and 23.72% year-over-year growth in adjusted EPS for the current quarter, reflecting anticipated operating leverage as programs scale.
Proponents of the bullish stance point to evidence of beat-and-raise dynamics in the last reported quarter, where revenue of 1.16 billion US dollars and adjusted EPS of 2.05 exceeded typical street estimates, accompanied by a 10.24% gross margin and a 4.28% net margin. The sequential 20.95% growth in net profit is seen as a tangible indicator of improving earnings quality and throughput. In this context, a revenue print near 1.23 billion US dollars coupled with a firm operating margin trajectory would set a favorable tone for the fiscal fourth quarter.
On the operational front, bullish analysts emphasize the balanced revenue base—Industrial at 478.67 million US dollars, Healthcare/Life Sciences at 472.87 million US dollars, and Aerospace/Defense at 212.22 million US dollars in the last reported quarter—which provides flexibility to maintain factory utilization and optimize mix. The Healthcare/Life Sciences segment, in particular, is often viewed as a reliable contributor to margin resilience during growth phases due to program complexity and longer lifecycles. The expected uplift in EBIT relative to revenue, inferred from current-quarter estimates, is seen as a continuation of this dynamic.
Valuation-wise, the constructive view rests on earnings growth translating into sustainable operating margins rather than purely volume-driven expansion. If management communicates steady progress in working-capital discipline and cash generation, it would align with expectations for a higher-quality earnings mix and reduce concerns about inventory build or receivable stretch during rapid growth periods. The CFO transition narrative, while closely watched, is not considered a structural impediment by bullish voices, provided that the financial playbook—cost discipline, capital allocation, and margin defense—remains consistent.
In sum, the majority view anticipates a quarter that validates the revenue and EPS growth trajectory already embedded in street models, with positive optionality from margin performance and program execution. Confirmation of the 1.23 billion US dollars revenue estimate, EPS near 2.12, and commentary consistent with ongoing EBIT expansion would likely reinforce the bullish framework and support a constructive setup into the fiscal fourth quarter.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments